(Neural cell lines derived from teratocarcinoma (NT2N) as graft source for cell transplantation: a new therapeutic strategy for chronic stroke patients)

Currently, Cerebrovascular accident (CVA) also known as stroke, is the third leading cause of disability and death worldwide. CVA is a sudden alteration of cerebral circulation, which results in neural cell death and consequently a temporary or permanent loss in certain neuronal functions. Therefore, in addition to working on prevention, in clinical practice is essential to have effective treatments aimed at avoiding neuronal dead. Unfortunately, the efficacy of the currently used therapeutic strategies is limited and, in most cases, patients suffering from stroke do not recover an adequate quality of life. This article presents cell therapy as a future alternative of interest in the treatment of chronic patients of CVA. This new therapy aims to replace the lost neuronal cells that are the main cause of disability in patients. Specifically, the review article presents recent progress on the use of teratocarcinoma-derived Ntera2/D1 neuronlike cells (NT2N cells), as graft source for cell transplantation in stroke, discussing the safety and efficacy demonstrated by preclinical and clinical trials made to date.